Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI-ARVC multicentre randomized trial
2024-517412-29-00Phase 3Authorised
- Sponsor
- National Institute of Cardiology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacubitril + valsartan in arrhythmogenic right ventricular cardiomyopathy (ARVC), sponsored by National Institute of Cardiology. Primary endpoints: Degree of left ventricular muscle fibrosis by CMR, Left ventricular ejection fraction by CMR and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
sacubitril + valsartan
03
Conditions
arrhythmogenic right ventricular cardiomyopathy (ARVC)
Beyond the preview
Go deeper on 2024-517412-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517412-29-00.